Expectations were for roughly $544 million of revenue and $1.94 of adjusted EPS; ICU Medical delivered $551.7 million and $2.37. That is a clear quarterly beat versus the published consensus, with revenue about 1% above expectations and adjusted EPS roughly 22% higher.
| Metric | Q2 2026 | Q2 2025 | Market reference | Read |
|---|---|---|---|---|
| Revenue | $551.7M | $548.9M | ~$544.1M consensus | Beat (Financial Statements; published consensus) |
| Adjusted diluted EPS | $2.37 | $2.10 | ~$1.94 consensus | Beat (Non-GAAP reconciliation; published consensus) |
| Adjusted EBITDA | $110.0M | $100.3M | — | Up 10% (Adjusted EBITDA reconciliation) |
| GAAP gross margin | 43% | 38% | — | Up 500 bps (Financial Highlights) |
| Free cash flow | $61.7M | $(8.5)M | — | Sharp improvement (Free Cash Flow reconciliation) |
| Full-year adjusted EBITDA guidance | $415M–$435M | $400M–$430M prior | — | Raised (Fiscal Year 2026 Guidance) |
| Full-year adjusted EPS guidance | $8.60–$9.00 | $7.75–$8.45 prior | — | Raised (Fiscal Year 2026 Guidance) |
The underlying growth was concentrated in the stronger businesses, especially Infusion Systems. Infusion Systems revenue rose 13% reported and 12% organically, while Consumables grew 5% organically; together they offset a 4% organic decline in Vital Care after adjusting for the prior IV Solutions divestiture. That mix is better than the headline 1% GAAP revenue growth suggests (Segment Revenue and Organic Revenue Reconciliation).
Profitability improved materially, but the quarter’s adjusted result includes meaningful exclusions. Gross margin expanded to 43% from 38%, and adjusted EBITDA rose 10%; however, adjusted EPS benefited from excluding $18.9 million of tariff refunds and other sizable adjustments, including $21.3 million of restructuring and $5.9 million of quality-related remediation. GAAP EPS was only $0.76, down from $1.43, though the prior-year figure included a $41.8 million business-sale gain (Income Statement; Non-GAAP Reconciliation).
The guidance increase is meaningful, but much of the GAAP upgrade is tax-driven rather than a sudden operating reset. The midpoint of adjusted EBITDA guidance increased from $415 million to $425 million, while adjusted EPS guidance midpoint rose from $8.10 to $8.80. GAAP net-income guidance more than doubled at the midpoint, from $35 million to $78 million, reflecting a substantially improved tax outlook and other below-operating-line items in addition to better earnings execution (Fiscal Year 2026 Guidance).
Cash generation and deleveraging add credibility to the positive read. Six-month operating cash flow reached $119.1 million versus $62.5 million, free cash flow rose to $89.3 million from $28.3 million, and debt declined by roughly $54.7 million during the period. Net leverage stood at 2.28x, leaving the balance sheet improved but still meaningfully leveraged (Cash Flow Statement; Net Leverage Ratio Calculation).
Read the original 8-K on SEC EDGAR ↗